Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation: Hematological Oncology

A.J.M. Ferreri, M. Sassone, P. Angelillo, F. Zaja, A. Re, A. Di Rocco, M. Spina, A. Fabbri, C. Stelitano, M. Frezzato, S. Volpetti, R. Zambello, C. Rusconi, D. De Lorenzo, E. Scarano, A. Arcari, G. Bertoldero, A. Nonis, T. Calimeri, S. PerroneC. Cecchetti, V. Tarantino, S. Steffanoni, M. Foppoli, F. Ciceri, M. Ponzoni

Research output: Contribution to journalArticlepeer-review

Abstract

We report final results of a phase II trial addressing efficacy and feasibility of lenalidomide maintenance in patients with chemosensitive relapse of diffuse large B-cell lymphoma (DLBCL) not eligible for or failed after autologous stem cell transplantation (ASCT). Patients with relapsed DLBCL who achieved at least a partial response to salvage chemoimmunotherapy were enrolled and treated with lenalidomide 25 mg/day for 21 of 28 days for 2 years or until progression or unacceptable toxicity. Primary endpoint was 1-year PFS. Forty-six of 48 enrolled patients were assessable. Most patients had IPI ≥2, advanced stage and extranodal disease before the salvage treatment that led to trial registration; 28 (61%) patients were older than 70 years. Lenalidomide was well tolerated. With the exception of neutropenia, grade-4 toxicities occurred in
Original languageEnglish
Pages (from-to)257-265
Number of pages9
JournalHematol. Oncol.
Volume38
Issue number3
DOIs
Publication statusPublished - 2020

Keywords

  • cell of origin
  • diffuse large B-cell lymphoma
  • immunomodulators
  • lenalidomide
  • maintenance
  • transformed high-grade lymphoma
  • angiogenesis inhibitor
  • adult
  • aged
  • anemia
  • Article
  • autologous stem cell transplantation
  • cancer chemotherapy
  • cancer immunotherapy
  • cancer recurrence
  • clinical article
  • constipation
  • diarrhea
  • diffuse large B cell lymphoma
  • drug efficacy
  • drug safety
  • febrile neutropenia
  • female
  • follow up
  • human
  • liver toxicity
  • male
  • multicenter study
  • nausea and vomiting
  • nephrotoxicity
  • neurotoxicity
  • neutropenia
  • phase 2 clinical trial
  • priority journal
  • progression free survival
  • rash
  • salvage therapy
  • thrombocytopenia
  • thrombosis
  • treatment failure
  • treatment response
  • clinical trial
  • maintenance chemotherapy
  • middle aged
  • pathology
  • prognosis
  • survival rate
  • tumor recurrence
  • very elderly
  • Adult
  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors
  • Female
  • Follow-Up Studies
  • Humans
  • Lenalidomide
  • Lymphoma, Large B-Cell, Diffuse
  • Maintenance Chemotherapy
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Prognosis
  • Salvage Therapy
  • Survival Rate

Fingerprint Dive into the research topics of 'Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation: Hematological Oncology'. Together they form a unique fingerprint.

Cite this